Transactions involving the acquisition of FDA-regulated firms and/or the licensing of products present unique challenges during the due diligence process. This session focuses on best practices and real-life examples of pitfalls that make or break the deal as they relate to intellectual property issues, clinical research, and regulatory requirements including:
- Projecting the scope of exclusionary rights on the product
- How the “useful” life cycle of a patent impacts transaction value and associated risks
- Evaluating the risks associated with patent litigation with respect to small molecules and follow-on biologics
- Understanding the clinical research and development program – how to maximize potential for success
- What can go wrong with clinical trials and practical suggestions to ensure compliance
- Identifying critical aspects of FDA regulatory authority relative to a diligence review
- Determining regulatory pathways towards product approval
- Prospecting opportunities to increase product life cycles
Presenters included:
- Ken Appleby, Of Counsel, Tax & Individual Planning Practice, Foley
- Gretchen Brodnicki, Dean for Faculty and Research Integrity, Harvard Medical School
- David Rosen, Co-Chair, Life Sciences Industry Team, Foley
- Larry Vernaglia, Partner, Regulated Industries Practice, Foley
Related Insights
November 13, 2025
Events
Shaping Tomorrow: Industry Trends Through Legal, Financial, and Economic Lenses
On September 13, Foley senior counsel Charles Gass will speak on the panel “Shaping Tomorrow: Industry Trends Through Legal, Financial, and Economic” during the Colorado Ambulatory Surgery Center Association’s (CASCA) Annual Conference & Trade Show. Gass is also CASCA’s general counsel.
July 17, 2025
Foley Viewpoints
Tricky Compliance Issues for Companies When an Executive Terminates Employment: Stock Options, Restricted Stock, and Other Equity Incentive Awards
Executive employment relationships are rarely permanent. When an executive or other senior-level employee terminates employment,…
July 17, 2025
Health Care Law Today
One Big Beautiful Bill: Slashed Budgets Will Disrupt the Medicaid Program
The new federal budget law, the One Big Beautiful Bill Act (the Act), enacted on July 4, 2025, makes dramatic changes to the Medicaid…